Incyte (INCY) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 3, 2022 7:00 AM EDTTotal product and royalty revenues of $728 million in Q122 (+20% Y/Y) Jakafi® (ruxolitinib) net product revenues of $544 million in Q122 (+17% Y/Y); raising the bottom end of full year guidance to new range of $2.33 to $2.40 billion Robust uptake of Opzelura (ruxolitinib) cream with over 38,000 new patients treated in the first quarter; meaningful progress with payers resulting in 146 million total lives now covered Positive 52-week data from the Phase 3 TRuE-V program evaluating ruxolitinib cream in patients with vitiligo presented at AAD 2022; ruxolitinib cream is currently under review in the U.S. and... More
